LIDDS and Recipharm, the contract development and manufacturing organisation (CDMO), have together set up a manufacturing line for LIDDS' novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden.
The manufacturing line is dedicated to the first product based on LIDDS' innovative NanoZolid® technology. Clinical trial material has already been produced and the facility is ready for future commercial manufacturing of Liproca® Depot or other pharmaceutical formulations based on the NanoZolid® technology. The manufacturing line has been adapted for GMP production and is industrialised according to a unique process invented by LIDDS, involving the installation of novel equipment that is new to the pharmaceutical industry.
"With the successful manufacturing performed at Recipharm, LIDDS can offer license agreements for Liproca® Depot with the advantage of having validated production in place, saving both time and money for pharma companies. In addition, we now have an established manufacturing facility ready for other NanoZolid® projects", says Monica Wallter CEO of LIDDS.
"We are proud of having reached this important milestone in the development of a new product allowing improved therapy for a serious disease. This has been achieved by the hard work and close collaboration of experts at both LIDDS and Recipharm. LIDDS is a very innovative company and it has been extremely rewarding to work with the team", says Torkel Gren, General Manager of Recipharm's facility in Solna.
For media enquiries, please contact Lindsay Baldry at ramarketing: firstname.lastname@example.org,
+ 44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /remarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.
LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through Monica Wallter, for publication on 20 July 2017 at 10:00 CET
LIDDS AB (publ) develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid® releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment. NanoZolid® technology allows for a controlled, sustained and customized release of medication for up to six months. NanoZolid® can integrate both small and large pharmaceutical molecules such as antibodies. The company's most advanced project, the prostate cancer product, Liproca® Depot containing 2-hydroxyflutamide, validates that the technology has a proven clinical effect. The prostate cancer project is currently in phase IIb. Industrial-scale production is produced in collaboration with Recipharm. LIDDS has active development projects where NanoZolid® is combined with antiandrogens, cytotoxic drugs and immuno-active agents. The LIDDS share is listed on Nasdaq, First North. Redeye AB is LIDDS certified adviser.
For more information, please visit www.lidds.se or liddspharma.com.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire